A Network And Pivot Model For Success In Cancer Drug Development

By Ben Comer, Chief Editor, Life Science Leader

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in development, no money, and a team of only four people. Five years later, after halting the development of its first licensed product, the Newark, CA-based precision oncology company awaits topline results from a pivotal Phase 3 trial in liposarcoma, which could open the door to a cancer therapy — milademetan — capable of treating as many as half of all known cancer types.